AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
ILAP intended to accelerate regulatory review process and facilitate patient access in U.K. for seriously debilitating and life-threatening diseases AVR-RD-02 has previously received Fast Track status from U.S. FDA and orphan drug designation in the U.S. and EU CAMBRIDGE, Mass.–(BUSINESS WIRE)–$AVRO—AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from … [Read more…]